Radiation Therapy in Oligometastatic Prostate Cancer.


Journal

International journal of radiation oncology, biology, physics
ISSN: 1879-355X
Titre abrégé: Int J Radiat Oncol Biol Phys
Pays: United States
ID NLM: 7603616

Informations de publication

Date de publication:
15 11 2022
Historique:
received: 10 05 2022
revised: 12 07 2022
accepted: 16 07 2022
pubmed: 26 7 2022
medline: 19 10 2022
entrez: 25 7 2022
Statut: ppublish

Résumé

Prostate cancer ranges from localized, low risk to metastatic, morbid disease. Although radiation therapy (RT) is commonly incorporated in the treatment of early disease or for palliation of symptomatic lesions, its role in extending survival in metastatic disease is less well-established. Here, we review the available evidence surrounding localized RT in the presence of oligometastatic disease and metastasis-directed therapy in both hormone-sensitive and hormone-resistant prostate cancer. We further outline potential future incorporation of RT as an immune-sensitizing therapy and the importance of highly sensitive imaging modalities in considering RT in metastatic disease.

Identifiants

pubmed: 35878715
pii: S0360-3016(22)00732-5
doi: 10.1016/j.ijrobp.2022.07.014
pii:
doi:

Substances chimiques

Hormones 0

Types de publication

Journal Article Review Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

684-692

Subventions

Organisme : NCI NIH HHS
ID : R01 CA105051
Pays : United States

Informations de copyright

Copyright © 2022 The Authors. Published by Elsevier Inc. All rights reserved.

Auteurs

Siven Chinniah (S)

Mayo Clinic Alix School of Medicine, Rochester, Minnesota.

Bradley Stish (B)

Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota.

Brian A Costello (BA)

Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota.

Lance Pagliaro (L)

Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota.

Daniel Childs (D)

Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota.

Fernando Quevedo (F)

Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota.

Fabrice Lucien (F)

Department of Urology, Mayo Clinic, Rochester, Minnesota.

Alan Bryce (A)

Department of Hematology and Oncology, Mayo Clinic, Phoenix, Arizona.

Sean S Park (SS)

Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota.

Jacob J Orme (JJ)

Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota. Electronic address: Orme.Jacob@mayo.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH